[1]
|
Seidah, N.G., et al. (2003) The Secretory Proprotein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation. Proceedings of the National Academy of Sciences of the United States of America, 100, 928-933. https://doi.org/10.1073/pnas.0335507100
|
[2]
|
Benjannet, S., et al. (2004) NARC-1/PCSK9 and Its Natural Mutants: Zymogen Cleavage and Effects on the Low Density Lipoprotein (LDL) Re-ceptor and LDL Cholesterol. The Journal of Biological Chemistry, 279, 48865-48875. https://doi.org/10.1074/jbc.M409699200
|
[3]
|
Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K. and Hobbs, H.H. (2005) Low LDL Cholesterol in Individuals of African Descent Resulting from Frequent Nonsense Mutations in PCSK9. Nature Genetics, 37, 161-165. https://doi.org/10.1038/ng1509
|
[4]
|
Hobbs, H.H. (2011) Sequence Variations in PCSK9, Low LDL, and Protec-tion against Coronary Heart Disease. The New England Journal of Medicine, 354, 1264-1272.
|
[5]
|
Stein, E.A., et al. (2012) Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. The New England Journal of Medicine, 366, 1108-1118. https://doi.org/10.1056/NEJMoa1105803
|
[6]
|
Goldstein, J. and Grown, M.S. (1997) The Srebp Pathway: Regulation of Cholesterol and Fatty Acid Metabolism by Proteolysis of a Membrane-Bound Transcription Factor. The FASEB Journal, 11, 331-340. https://doi.org/10.1016/S0092-8674(00)80213-5
|
[7]
|
Horton, J.D., Cohen, J.C. and Hobbs, H.H. (2009) PCSK9: A Convertase That Coordinates LDL Catabolism. The Journal of Lipid Research, 50, S172-S177. https://doi.org/10.1194/jlr.R800091-JLR200
|
[8]
|
Poirier, S., et al. (2008) The Proprotein Convertase PCSK9 In-duces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2. The Journal of Biological Chemistry, 283, 2363-2372. https://doi.org/10.1074/jbc.M708098200
|
[9]
|
Pitts, R.N. and Eckel, R.H. (2014) The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology. European Cardiology Review, 9, 65-70. https://doi.org/10.15420/ecr.2014.9.2.65
|
[10]
|
Lo Surdo, P., et al. (2011) Mechanistic Implications for LDL Recep-tor Degradation from the PCSK9/LDLR Structure at Neutral pH. EMBO Reports, 12, 1300-1305. https://doi.org/10.1038/embor.2011.205
|
[11]
|
Catapano, A.L. and Papadopoulos, N. (2013) The Safety of Thera-peutic Monoclonal Antibodies: Implications for Cardiovascular Disease and Targeting the PCSK9 Pathway. Atheroscle-rosis, 228, 18-28. https://doi.org/10.1016/j.atherosclerosis.2013.01.044
|
[12]
|
He, N.Y., et al. (2017) Lowering Serum Lipids via PCSK9-Targeting Drugs: Current Advances and Future Perspectives. Acta Pharmacologica Sinica, 38, 301-311. https://doi.org/10.1038/aps.2016.134
|
[13]
|
McKenney, J.M., Koren, M.J., Kereiakes, D.J., Hanotin, C., Ferrand, A.C. and Stein, E.A. (2012) Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients with Primary Hypercholesterolemia Receiving Ongoing Sta-ble Atorvastatin Therapy. Journal of the American College of Cardiology, 59, 2344-2353. https://doi.org/10.1016/j.jacc.2012.03.007
|
[14]
|
Stein, E.A., et al. (2012) Effect of a Monoclonal Antibody to PCSK9, REGN727/SAR236553, to Reduce Low-Density Lipoprotein Cholesterol in Patients with Heterozygous Famili-al Hypercholesterolaemia on Stable Statin Dose with or without Ezetimibe Therapy: A Phase 2 Randomised Controlle. The Lancet, 380, 29-36. https://doi.org/10.1016/S0140-6736(12)60771-5
|
[15]
|
White, H.D., et al. (2019) Effects of Alirocumab on Types of Myocardial Infarction: Insights from the ODYSSEY OUTCOMES Trial. European Heart Journal, 40, 2801-2809. https://doi.org/10.1093/eurheartj/ehz299
|
[16]
|
Cicero, A.F.G., Tartagni, E. and Ertek, S. (2014) Efficacy and Safety Profile of Evolocumab (AMG145), an Injectable Inhibitor of the Proprotein Convertase Subtilisin/Kexin Type 9: The Available Clinical Evidence. Expert Opinion on Biological Therapy, 14, 863-868. https://doi.org/10.1517/14712598.2014.902929
|
[17]
|
Dixon, D.L., Buckley, L.F., Trankle, C.R., Kadariya, D. and Abbate, A. (2017) Clinical Utility of Evolocumab in the Management of Hyperlipidemia: Patient Selection and Fol-low-Up. Drug Design, Development and Therapy, 11, 2121-2129. https://doi.org/10.2147/DDDT.S114091
|
[18]
|
Khan, A.R., et al. (2017) Increased Risk of Adverse Neurocognitive Outcomes with Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors. Circulation: Cardiovascular Quality and Outcomes, 10, e003153. https://doi.org/10.1161/CIRCOUTCOMES.116.003153
|
[19]
|
Sabatine, M.S., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376, 1713-1722. https://doi.org/10.1056/NEJMoa1615664
|
[20]
|
Ling, H., Burns, T.L. and Hilleman, D.E. (2014) An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol. Cardiovascular Therapeutics, 32, 82-88. https://doi.org/10.1111/1755-5922.12056
|
[21]
|
Fazio, S., et al. (2018) Effects of 12 Weeks of Treatment with Intra-venously Administered Bococizumab, a Humanized Monoclonal Antibody Blocking Proprotein Convertase Subtil-isin/Kexin Type 9, in Hypercholesterolemic Subjects on High-Dose Statin. Cardiovascular Therapeutics, 36, 1-9. https://doi.org/10.1111/1755-5922.12308
|
[22]
|
Foltz, I.N., Karow, M. and Wasserman, S.M. (2013) Evolution and Emergence of Therapeutic Monoclonal Antibodies what Cardiologists Need to Know. Circulation, 127, 2222-2230. https://doi.org/10.1161/CIRCULATIONAHA.113.002033
|
[23]
|
Ridker, P.M., et al. (2017) Lipid-Reduction Varia-bility and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine, 376, 1517-1526. https://doi.org/10.1056/NEJMoa1614062
|
[24]
|
Dahagam, C., et al. (2016) PCSK9 Inhibitors and Their Role in High-Risk Patients in Reducing LDL Cholesterol Levels: Alirocumab. Future Cardiology, 12, 149-157. https://doi.org/10.2217/fca.15.88
|
[25]
|
Strilchuck, L., Fogacci, F. and Cicero, A.F. (2019) Safety and Tolerability of Injectable Lipid-Lowering Drugs: An Update of Clinical Data. Expert Opinion on Drug Safety, 18, 611-621. https://doi.org/10.1080/14740338.2019.1620730
|
[26]
|
Liu, M., et al. (2010) PCSK9 Is Not Involved in the Degra-dation of LDL Receptors and BACE1 in the Adult Mouse Brain. The Journal of Lipid Research, 51, 2611-2618. https://doi.org/10.1194/jlr.M006635
|
[27]
|
Koren, M.J., et al. (2014) Efficacy and Safety of Longer-Term Admin-istration of Evolocumab (AMG 145) in Patients with Hypercholesterolemia: 52-Week Results from the Open-Label Study of Long-Term Evaluation against LDL-C (OSLER) Randomized Trial. Circulation, 129, 234-243. https://doi.org/10.1161/CIRCULATIONAHA.113.007012
|
[28]
|
Adorni, M.P., Ruscica, M., Ferri, N., Bernini, F. and Zimetti, F. (2019) Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Im-plication for Alzheimer’s Disease. Frontiers in Aging Neuroscience, 11, 120. https://doi.org/10.3389/fnagi.2019.00120
|